DLBCL patient FAQ: 20 questions about treatment, relapse and care in China

DLBCL questions often need pathology, stage, previous treatment and physical fitness to be considered together. These 20 answers help prepare a consultation rather than provide a personal prescription or outcome guarantee. Bring actual drug names, doses and dates if treatment has already occurred; saying chemotherapy was given is not enough to select the next step.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

No. DLBCL is an aggressive lymphoma and usually needs prompt treatment, but many patients can receive therapy with cure as the goal, including some with advanced-stage disease. [S1] Growth speed and treatment sensitivity are different questions. Prioritize an adequate diagnosis and a complete feasible regimen. Airway, bowel or neurological compression can make the clinical situation urgent and should be assessed rather than waiting for an ordinary appointment.
Side-effect intensity does not measure anticancer effect. People react differently, and supportive medicines can reduce discomfort without proving that the anticancer treatment is weaker. [S20] Response is assessed with appropriate clinical tests. Do not endure dehydration or severe pain to feel that treatment is strong enough. Report symptoms that affect eating, walking or sleep. Dose suitability is assessed from body size, organs, the protocol and actual administration records rather than another patient's experience.
Bring final pathology, administered drugs, dose changes, response, radiation or cell-product records, unresolved toxicity and prevention plans. Confirm that a home hematologist accepts the handover. Follow-up testing should reflect symptoms and disease course rather than treating frequent PET as universal. [S12] Fertility, vaccines, work and activity require individualized advice. [S9,S14] Report new symptoms and use local emergency care when needed. Regular follow-up without specific responsibilities and dates is not a complete cross-border care plan.

Quick answer

Full guide

1. Does rapid growth mean DLBCL cannot be cured?

No. DLBCL is an aggressive lymphoma and usually needs prompt treatment, but many patients can receive therapy with cure as the goal, including some with advanced-stage disease. [S1] Growth speed and treatment sensitivity are different questions. Prioritize an adequate diagnosis and a complete feasible regimen. Airway, bowel or neurological compression can make the clinical situation urgent and should be assessed rather than waiting for an ordinary appointment.

2. Can a blood test or PET scan establish the diagnosis?

Not alone. These tests may provide clues or show distribution, while diagnosis generally requires tissue and appropriate immunological or genetic studies. [S2] Fine-needle sampling can be insufficient for full classification, requiring core or excision biopsy. Ask whether the specimen is adequate and which results remain pending. A suspected lymphoma result should not silently become a definitive DLBCL prescription. Extra tests should resolve a real question rather than simply increase the size of the investigation package.

3. Are double expression and double hit the same?

They are different findings. Double expression generally refers to MYC and BCL2 protein staining, whereas rearrangement-defined categories require genetic testing. Protein positivity does not establish a gene rearrangement, and Ki-67 does not replace FISH. [S3] Keep the individual gene results and full classification wording. If unclear, request hematopathology review before selecting intensified treatment. Different rearrangement combinations also need interpretation under the classification system used by the laboratory.

4. Does stage IV mean treatment can only relieve symptoms?

Not necessarily. Lymphoma stage describes distribution and should not be interpreted through the meaning of advanced stage in another solid cancer. Stage IV DLBCL can still be approached with curative intent. [S1] Fitness, organ function and infection also affect feasibility. The clinician should state the goal directly. If lower intensity is proposed, ask whether the reason is frailty, a specific organ risk or another limitation and whether supportive measures could change it.

5. Why not remove the lump and finish treatment?

DLBCL usually requires systemic medicines even when one mass is conspicuous. Surgery commonly provides diagnostic tissue or addresses complications such as perforation, obstruction or severe bleeding. [S1] Removal of a node is followed by a plan based on pathology and staging. Gastrointestinal involvement does not automatically require extensive preventive surgery. Severe new abdominal pain, black stools or faintness needs assessment rather than being dismissed as ordinary treatment nausea.

6. How are R-CHOP and Pola-R-CHP chosen?

The choice considers pathology, stage, IPI, organs and nerve function. Pola-R-CHP replaces vincristine with polatuzumab; it is not an extra drug to add independently to R-CHOP. The FDA first-line indication includes specified adult pathology and IPI criteria. [S4] Ask how the evidence fits you and verify Chinese approval and supply separately. A patient responding to a suitable existing regimen should not switch midway solely after reading publicity about a newer medicine.

7. Can an older patient still receive curative treatment?

Some can. Mobility, nutrition, cognition, organ function and caregiver support contribute alongside age. [S3] One patient may tolerate standard treatment while another needs an adjusted regimen. Reduction does not automatically mean abandonment, but it does not remove risk. Clarify the goal, response assessment and support plan. Families should describe actual daily function and report falls, eating difficulty or memory problems instead of concealing them to obtain a stronger regimen.

8. How long does treatment usually take?

First-line immunochemotherapy commonly occupies months, with cycles and intervals determined by risk and the regimen; selected localized plans add radiation. Oral medicines, count nadirs and recovery follow infusion, so infusion days alone do not determine residence time. [S20] Relapse transplantation or CAR T treatment adds collection, manufacture or observation. [S11,S13] Ask for an anticipated calendar and delay conditions. Flights and housing should fit the clinical schedule rather than dictate dose intervals.

9. Can I omit remaining cycles after the lump disappears?

Do not shorten treatment yourself. Symptom improvement is useful information but does not replace the regimen's response criteria. Shorter courses require specific clinical conditions and a coherent strategy chosen by the team. [S1] If toxicity, cost or travel makes continuation difficult, raise it early and discuss a feasible adjustment. Unreported skipped cycles can later make doctors assume that a complete course was delivered, affecting interpretation of both response and relapse.

10. Does residual PET uptake always mean failure?

No. Residual structure can be scar tissue, and uptake can reflect inflammation. Timing, baseline comparison and symptoms matter; selected findings need review, reassessment or biopsy before treatment is changed. [S3] Ask whether the report describes a mass, metabolic uncertainty or confirmed active lymphoma. Interim and end-of-treatment results also have different roles. An isolated Deauville score should not prompt self-directed stopping or an automatic request for transplantation.

11. Do little hair loss and mild nausea mean the dose is inadequate?

Side-effect intensity does not measure anticancer effect. People react differently, and supportive medicines can reduce discomfort without proving that the anticancer treatment is weaker. [S20] Response is assessed with appropriate clinical tests. Do not endure dehydration or severe pain to feel that treatment is strong enough. Report symptoms that affect eating, walking or sleep. Dose suitability is assessed from body size, organs, the protocol and actual administration records rather than another patient's experience.

12. Which symptoms need urgent medical attention?

Fever of 38°C or above, chills, breathlessness, chest pain, confusion, persistent bleeding, severe abdominal pain or inability to drink needs prompt contact and emergency assessment when directed. Recent chemotherapy increases concern about infection. [S8] Do not wait for a new count to confirm neutropenia or rely only on fever reducers. Carry treatment dates, regimen, allergies and contacts. Local emergency care can proceed while the China center is contacted.

13. Should I disclose previous hepatitis B without current symptoms?

Yes. Immune treatment can require hepatitis B testing, antiviral prevention and monitoring even after an earlier infection. [S3] Retain the original results and medicine history rather than writing that hepatitis resolved. The last anticancer infusion does not automatically end preventive treatment. Obtain review and stopping criteria and confirm local prescribing and laboratory access before returning home. If a medicine is unavailable, the two teams should arrange an appropriate alternative rather than leaving the patient to substitute it.

14. Does everyone need a lumbar puncture or CNS prophylaxis?

No. Neurological symptoms, selected extranodal sites and other risk features affect whether cerebrospinal fluid testing or prophylaxis is discussed. Benefit, kidney function, toxicity and possible disruption of systemic therapy must be considered together. [S3] New persistent headache, visual changes, weakness or seizure should be reported promptly. The need for a test and the need for preventive medication are related but distinct decisions; another patient's procedure list does not establish your indication.

15. Is CAR T the only treatment after relapse?

No. Repeat pathology, relapse interval, earlier response and fitness guide the options. Some early relapses or refractory cases merit early CAR T assessment; selected later, salvage-sensitive cases may undergo autologous transplantation. Bispecific antibodies, other combinations or trials may fit other patients. [S5,S6,S7,S13] Every pathway needs a waiting-period plan and alternatives. A long list of drug names does not mean they can be used in any order or guarantee the next response.

16. Can I go straight home after a single CAR T infusion?

Do not plan solely around the infusion count. Collection, manufacturing, possible bridging and lymphodepletion precede it, with observation for immune toxicity, infection and counts afterward. [S11] The product and center determine admission, nearby residence, caregiver and travel conditions. Removal of certain FDA REMS requirements did not remove clinical risks. [S19] Obtain your complete schedule rather than using another patient's uncomplicated discharge date as evidence of readiness.

17. Is a new medicine or trial necessarily better than standard care?

No. Randomized trials, early studies and single-arm response rates answer different questions in different populations. POLARIX five-year follow-up supported a progression-free survival advantage for Pola-R-CHP, while the overall-survival difference was not statistically significant at that analysis. [S24] It cannot become a universal lifespan promise. A trial requires confirmation of local availability, criteria, risks, usual alternatives and care after withdrawal. [S16,S17] Do not stop necessary treatment for an unconfirmed research place.

18. How much money should I prepare in Chinese yuan?

A dependable total requires an individual plan. Ask the hospital to itemize pathology, drugs and doses, cycles, admission, support, radiation or cellular stages and complications. No verified personal quotation was obtained for this article, so a range would be invented. [S10] Add housing, caregiver, travel and home testing. Chinese resident insurance payments cannot be assumed for international self-pay care. Free study medicine also does not establish that every clinical and living expense is covered.

19. When is a China consultation worth considering?

Disputed pathology, complex relapse or cellular-therapy assessment, or a confirmed relevant specialist resource can justify remote inquiry first. Reliable diagnosis and timely suitable local treatment may not require moving the course. Fever, severe cytopenias, respiratory problems or neurological emergencies should be managed locally before travel. [S14,S22] The receiving hospital should confirm the purpose, records, timing and ongoing responsibility. Country or institutional reputation alone cannot guarantee a better personal outcome.

20. How should follow-up and recovery be arranged at home?

Bring final pathology, administered drugs, dose changes, response, radiation or cell-product records, unresolved toxicity and prevention plans. Confirm that a home hematologist accepts the handover. Follow-up testing should reflect symptoms and disease course rather than treating frequent PET as universal. [S12] Fertility, vaccines, work and activity require individualized advice. [S9,S14] Report new symptoms and use local emergency care when needed. Regular follow-up without specific responsibilities and dates is not a complete cross-border care plan.